Status:
COMPLETED
Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis
Lead Sponsor:
Clinical Hospital Merkur
Collaborating Sponsors:
University Medical Centre Ljubljana
University Hospital Rijeka
Conditions:
Kidney Transplantation
Kidney Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Development of chronic changes (scarring) in transplanted kidney tissue is a major cause of long-term kidney function deterioration and ultimately graft loss. It results from both immunologic and non-...
Eligibility Criteria
Inclusion
- first kidney or kidney-pancreas transplantation
- CDC PRA \<=20%
Exclusion
- dual kidney transplantation
- AB0 incompatible transplantation
- 0 biopsy ci, ct, cv, or ah score \>=2
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT01860183
Start Date
May 1 2013
End Date
June 1 2016
Last Update
October 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Hospital Merkur
Zagreb, HR, Croatia, 10000